{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:39:05Z","timestamp":1789994345310,"version":"4.0.1"},"reference-count":137,"publisher":"National Institute for Health and Care Research","issue":"87","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["14\/03\/01"],"award-info":[{"award-number":["14\/03\/01"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"Background<\/jats:title>There is no single definitive test to identify prostate cancer in men. Biopsies are commonly used to obtain samples of prostate tissue for histopathological examination. However, this approach frequently misses cases of cancer, meaning that repeat biopsies may be necessary to obtain a diagnosis. The PROGENSA\u00ae<\/jats:sup>prostate cancer antigen 3 (PCA3) assay (Hologic Gen-Probe, Marlborough, MA, USA) and the Prostate Health Index (phi; Beckman Coulter Inc., Brea, CA, USA) are two new tests (a urine test and a blood test, respectively) that are designed to be used to help clinicians decide whether or not to recommend a repeat biopsy.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate the clinical effectiveness and cost-effectiveness of the PCA3 assay and the phi in the diagnosis of prostate cancer.<\/jats:p><\/jats:sec>Data sources<\/jats:title>Multiple publication databases and trial registers were searched in May 2014 (from 2000 to May 2014), including MEDLINE, EMBASE, The Cochrane Library, ISI Web of Science, Medion, Aggressive Research Intelligence Facility database, ClinicalTrials.gov, International Standard Randomised Controlled Trial Number Register and World Health Organization International Clinical Trials Registry Platform.<\/jats:p><\/jats:sec>Review methods<\/jats:title>The assessment of clinical effectiveness involved three separate systematic reviews, namely reviews of the analytical validity, the clinical validity of these tests and the clinical utility of these tests. The assessment of cost-effectiveness comprised a systematic review of full economic evaluations and the development of a de novo economic model.<\/jats:p><\/jats:sec>Setting<\/jats:title>The perspective of the evaluation was the NHS in England and Wales.<\/jats:p><\/jats:sec>Participants<\/jats:title>Men suspected of having prostate cancer for whom the results of an initial prostate biopsy were negative or equivocal.<\/jats:p><\/jats:sec>Interventions<\/jats:title>The use of the PCA3 score or phi in combination with existing tests (including histopathology results, prostate-specific antigen level and digital rectal examination), multiparametric magnetic resonance imaging and clinical judgement.<\/jats:p><\/jats:sec>Results<\/jats:title>In addition to documents published by the manufacturers, six studies were identified for inclusion in the analytical validity review. The review identified issues concerning the precision of the PCA3 assay measurements. It also highlighted issues relating to the storage requirements and stability of samples intended for analysis using the phi assay. Fifteen studies met the inclusion criteria for the clinical validity review. These studies reported results for 10 different clinical comparisons. There was insufficient evidence to enable the identification of appropriate test threshold values for use in a clinical setting. In addition, the implications of adding either the PCA3 assay or the phi to clinical assessment were not clear. Furthermore, the addition of the PCA3 assay or the phi to clinical assessment plus magnetic resonance imaging was not found to improve discrimination. No published papers met the inclusion criteria for either the clinical utility review or the cost-effectiveness review. The results from the cost-effectiveness analyses indicated that using either the PCA3 assay or the phi in the NHS was not cost-effective.<\/jats:p><\/jats:sec>Limitations<\/jats:title>The main limitations of the systematic review of clinical validity are that the review conclusions are over-reliant on findings from one study, the descriptions of clinical assessment vary widely within reviewed studies and many of the reported results for the clinical validity outcomes do not include either standard errors or confidence intervals.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>The clinical benefit of using the PCA3 assay or the phi in combination with existing tests, scans and clinical judgement has not yet been confirmed. The results from the cost-effectiveness analyses indicate that the use of these tests in the NHS would not be cost-effective.<\/jats:p><\/jats:sec>Study registration<\/jats:title>This study is registered as PROSPERO CRD42014009595.<\/jats:p><\/jats:sec>Funding<\/jats:title>The National Institute for Health Research Health Technology Assessment programme.<\/jats:p><\/jats:sec>","DOI":"10.3310\/hta19870","type":"journal-article","created":{"date-parts":[[2015,10,29]],"date-time":"2015-10-29T09:35:30Z","timestamp":1446111330000},"page":"1-192","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":68,"title":["The clinical effectiveness and cost-effectiveness of the PROGENSA\u00ae prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation"],"prefix":"10.3310","volume":"19","clinical-trial-number":[{"clinical-trial-number":"isrctn55398410","registry":"10.18810\/isrctn","type":"results"}],"author":[{"given":"Amanda","family":"Nicholson","sequence":"first","affiliation":[{"name":"Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Mahon","sequence":"additional","affiliation":[{"name":"Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Boland","sequence":"additional","affiliation":[{"name":"Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Beale","sequence":"additional","affiliation":[{"name":"Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Dwan","sequence":"additional","affiliation":[{"name":"Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Fleeman","sequence":"additional","affiliation":[{"name":"Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliet","family":"Hockenhull","sequence":"additional","affiliation":[{"name":"Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yenal","family":"Dundar","sequence":"additional","affiliation":[{"name":"Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2015,10]]},"reference":[{"key":"key20151028091053177_ref1-bib1","volume-title":"Diagnostic Value of Systematic Prostate Biopsy Methods in the Investigation for Prostate Cancer: A Systematic Review","author":"Eichler","year":"2005"},{"key":"key20151028091053177_ref1-bib2","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1097\/00000478-198812000-00001","article-title":"Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread","volume":"12","author":"McNeal","year":"1988","journal-title":"Am J Surg Pathol"},{"key":"key20151028091053177_ref1-bib3","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/00000478-198808000-00003","article-title":"Normal histology of the prostate","volume":"12","author":"McNeal","year":"1988","journal-title":"Am J Surg Pathol"},{"key":"key20151028091053177_ref1-bib4","volume-title":"How is Prostate Cancer Staged?","author":"American Cancer Society","year":"2013"},{"key":"key20151028091053177_ref1-bib5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.eururo.2013.06.051","article-title":"Early detection of prostate cancer: European Association of Urology recommendation","volume":"64","author":"Heidenreich","year":"2013","journal-title":"Eur Urol"},{"key":"key20151028091053177_ref1-bib6","volume-title":"Prostate Cancer Treatment","author":"Prostate Cancer UK","year":"2014"},{"key":"key20151028091053177_ref1-bib7","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1210\/er.2002-0032","article-title":"Androgen receptor in prostate cancer","volume":"25","author":"Heinlein","year":"2004","journal-title":"Endocr Rev"},{"key":"key20151028091053177_ref1-bib8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0022-5347(05)00034-0","article-title":"Secondary hormonal therapy for advanced prostate cancer","volume":"175","author":"Lam","year":"2006","journal-title":"J Urol"},{"key":"key20151028091053177_ref1-bib9","volume-title":"Prostate Cancer Incidence Statistics","author":"Cancer Research UK","year":"2014"},{"key":"key20151028091053177_ref1-bib10","volume-title":"Prostate Cancer Survival Statistics","author":"Cancer Research UK","year":"2014"},{"key":"key20151028091053177_ref1-bib11","volume-title":"Prostate Cancer: Diagnosis and Treatment","author":"National Collaborating Centre for Cancer","year":"2014"},{"key":"key20151028091053177_ref1-bib12","volume-title":"Prostate Cancer Mortality Statistics","author":"Cancer Research UK","year":"2014"},{"key":"key20151028091053177_ref1-bib13","doi-asserted-by":"publisher","first-page":"e002317","DOI":"10.1136\/bmjopen-2012-002317","article-title":"Patient reported outcomes of cancer survivors in England 1\u20135 years after diagnosis: a cross-setional survey","volume":"3","author":"Glaser","year":"2013","journal-title":"BMJ Open"},{"issue":"20","key":"key20151028091053177_ref1-bib14","doi-asserted-by":"publisher","DOI":"10.3310\/hta17200","article-title":"The diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy: a systematic review and economic evaluation","volume":"17","author":"Mowatt","year":"2013","journal-title":"Health Technol Assess"},{"key":"key20151028091053177_ref1-bib15","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/j.1442-2042.2011.02798.x","article-title":"Prostate cancer detection after a negative prostate biopsy: lessons learnt in the Cleveland Clinic experience","volume":"18","author":"Zaytoun","year":"2011","journal-title":"Int J Urol"},{"key":"key20151028091053177_ref1-bib16","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1111\/j.1464-410X.2011.10809.x","article-title":"Optimising repeat prostate biopsy decisions and procedures","volume":"109","author":"Kirby","year":"2011","journal-title":"BJU Int"},{"key":"key20151028091053177_ref1-bib17","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.eururo.2011.07.036","article-title":"The optimal rebiopsy prostatic scheme depends on patient clinical characteristics: results of a recursive partitioning analysis based on a 24-core systematic scheme","volume":"60","author":"Scattoni","year":"2011","journal-title":"Eur Urol"},{"key":"key20151028091053177_ref1-bib18","volume-title":"National Schedule of Reference Costs: The Main Schedule","author":"Department of Health (DH)","year":"2013"},{"key":"key20151028091053177_ref1-bib19","volume-title":"Prostate Cancer Risk Management Programme. Information for Primary Care; PSA Testing in Asymptomatic Men","author":"Burford","year":"2010"},{"key":"key20151028091053177_ref1-bib20","volume-title":"Prostate Cancer Risk Management Programme. Undertaking a Transrectal Ultrasound Guided Biopsy of the Prostate","author":"NHS Cancer Screening Programmes","year":"2006"},{"key":"key20151028091053177_ref1-bib21","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/S0090-4295(97)00306-3","article-title":"The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer","volume":"50","author":"Norberg","year":"1997","journal-title":"Urology"},{"key":"key20151028091053177_ref1-bib22","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/S0022-5347(05)65851-X","article-title":"Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study","volume":"166","author":"Djavan","year":"2001","journal-title":"J Urol"},{"key":"key20151028091053177_ref1-bib23","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/sj.pcan.4500730","article-title":"Prostate cancer detection and tumor characteristics in men with multiple biopsy sessions","volume":"7","author":"Lujan","year":"2004","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"key20151028091053177_ref1-bib24","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/S0090-4295(02)01950-7","article-title":"Predictors of cancer in repeat extended multisite prostate biopsy in men with previous negative extended multisite biopsy","volume":"60","author":"Mian","year":"2002","journal-title":"Urology"},{"key":"key20151028091053177_ref1-bib25","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1043\/1543-2165-133.11.1810","article-title":"Current perspectives on the Gleason grading of prostate cancer","volume":"133","author":"Shah","year":"2009","journal-title":"Arch Pathol Lab Med"},{"key":"key20151028091053177_ref1-bib26","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1097\/00000478-200004000-00001","article-title":"Gleason score 2\u20134 adenocarcinoma of the prostate on needle biopsy: a diagnosis that should not be made","volume":"24","author":"Epstein","year":"2000","journal-title":"Am J Surg Pathol"},{"key":"key20151028091053177_ref1-bib27","volume-title":"Towards a Consensus Protocol on Prostate Biopsies: Indications, Techniques and Assessment","author":"University of Liverpool","year":"2003"},{"key":"key20151028091053177_ref1-bib28","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1097\/01.pas.0000173646.99337.b1","article-title":"The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma","volume":"29","author":"Epstein","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"key20151028091053177_ref1-bib29","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1001\/jama.293.17.2095","article-title":"20-year outcomes following conservative management of clinically localized prostate cancer","volume":"293","author":"Albertsen","year":"2005","journal-title":"JAMA"},{"key":"key20151028091053177_ref1-bib30","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/1097-0142(19930201)71:3+<933::AID-CNCR2820711408>3.0.CO;2-L","article-title":"Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer","volume":"71","author":"Stamey","year":"1993","journal-title":"Cancer"},{"key":"key20151028091053177_ref1-bib31","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.juro.2010.08.082","article-title":"A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial","volume":"185","author":"Wolters","year":"2011","journal-title":"J Urol"},{"key":"key20151028091053177_ref1-bib32","doi-asserted-by":"publisher","first-page":"121","DOI":"10.5489\/cuaj.11085","article-title":"Pre-treatment risk stratification of prostate cancer patients: a critical review","volume":"6","author":"Rodrigues","year":"2012","journal-title":"Can Urol Assoc J"},{"key":"key20151028091053177_ref1-bib33","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1038\/bjc.2014.192","article-title":"Identification of pathologically insignificant prostate cancer is not accurate in unscreened men","volume":"110","author":"Shaw","journal-title":"Br J Cancer"},{"key":"key20151028091053177_ref1-bib34","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D\u2019Amico","year":"1998","journal-title":"JAMA"},{"key":"key20151028091053177_ref1-bib35","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0022-5347(17)37393-7","article-title":"Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer","volume":"147","author":"Benson","year":"1992","journal-title":"J Urol"},{"key":"key20151028091053177_ref1-bib36","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/j.1445-2197.2009.05055.x","article-title":"Prostate-specific antigen velocity (PSAV): a practical role for PSA?","volume":"79","author":"Thanigasalam","year":"2009","journal-title":"ANZ J Surg"},{"key":"key20151028091053177_ref1-bib37","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/ncpuro1290","article-title":"Risk factors for prostate cancer","volume":"6","author":"Patel","year":"2009","journal-title":"Nat Clin Pract Urol"},{"key":"key20151028091053177_ref1-bib38","volume-title":"Risk Calculators","author":"SWOP \u2013 The Prostate Cancer Research Foundation, Rotterdam"},{"key":"key20151028091053177_ref1-bib39","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.ejca.2010.11.012","article-title":"Prediction of prostate cancer in unscreened men: external validation of a risk calculator","volume":"47","author":"van Vugt","year":"2011","journal-title":"Eur J Cancer"},{"key":"key20151028091053177_ref1-bib40","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1093\/jnci\/djj131","article-title":"Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial","volume":"98","author":"Thompson","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"key20151028091053177_ref1-bib41","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1097\/01.ju.0000158039.94467.5d","article-title":"Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen","volume":"173","author":"Karakiewicz","year":"2005","journal-title":"J Urol"},{"key":"key20151028091053177_ref1-bib42","volume-title":"Multi-Parametric Prostate Cancer Staging Exam","author":"University of California San Francisco","year":"2014"},{"key":"key20151028091053177_ref1-bib43","doi-asserted-by":"publisher","first-page":"522","DOI":"10.4103\/1008-682X.122864","article-title":"Targeted prostate biopsy: value of multiparametric magnetic resonance imaging in detection of localized cancer","volume":"16","author":"Le","year":"2014","journal-title":"Asian J Androl"},{"key":"key20151028091053177_ref1-bib44","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/MOU.0b013e32835ad3ee","article-title":"MRI\u2013ultrasound fusion for guidance of targeted prostate biopsy","volume":"23","author":"Marks","year":"2013","journal-title":"Curr Opin Urol"},{"key":"key20151028091053177_ref1-bib45","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.juro.2013.02.018","article-title":"PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study","volume":"190","author":"Gittelman","year":"2013","journal-title":"J Urol"},{"key":"key20151028091053177_ref1-bib46","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.eururo.2008.06.071","article-title":"Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy","volume":"54","author":"Haese","year":"2008","journal-title":"Eur Urol"},{"key":"key20151028091053177_ref1-bib47","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1590\/S1677-55382012000400008","article-title":"PCA3 score and prostate cancer diagnosis at repeated saturation biopsy. Which cut-off: 20 or 35?","volume":"38","author":"Pepe","year":"2012","journal-title":"Int Braz J Urol"},{"key":"key20151028091053177_ref1-bib48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cca.2007.11.003","article-title":"A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy","volume":"389","author":"Sokoll","year":"2008","journal-title":"Clin Chim Acta"},{"key":"key20151028091053177_ref1-bib49","volume-title":"Diagnosis and Monitoring of Prostate Cancer: Progensa PCA3 Assay and Prostate Health Index (PHI): Final Scope","author":"National Institute for Health and Care Excellence","year":"2014"},{"key":"key20151028091053177_ref1-bib50","volume-title":"Summary of Safety and Effectiveness Data. PMA P100033: PROGENSA PCA3 Assay","author":"Food and Drug Administration","year":"2012"},{"key":"key20151028091053177_ref1-bib51","author":"Gen-Probe","journal-title":"Pack Insert for PROGENSA PCA3 Assay"},{"key":"key20151028091053177_ref1-bib52","author":"Food and Drug Administration","year":"2012","journal-title":"PMA Approval. PROGENSA PCA3 Assay"},{"key":"key20151028091053177_ref1-bib53","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.urology.2005.10.052","article-title":"Study Group. A meta-analysis of the performance characteristics of the free prostate-specific antigen test","volume":"67","author":"Lee","year":"2006","journal-title":"Urology"},{"key":"key20151028091053177_ref1-bib54","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.eururo.2005.04.015","article-title":"Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2\u201310 ng\/ml: systematic review and meta-analysis","volume":"48","author":"Roddam","year":"2005","journal-title":"Eur Urol"},{"key":"key20151028091053177_ref1-bib55","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.eururo.2010.02.003","article-title":"Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection","volume":"57","author":"Jansen","year":"2010","journal-title":"Eur Urol"},{"key":"key20151028091053177_ref1-bib56","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1016\/j.juro.2009.12.056","article-title":"[\u20132]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study","volume":"183","author":"Le","year":"2010","journal-title":"J Urol"},{"key":"key20151028091053177_ref1-bib57","author":"Beckman Coulter","year":"2011","journal-title":"Draft Directional Insert. Access Immunoassay Systems. Hybritech p2PSA"},{"key":"key20151028091053177_ref1-bib58","volume-title":"Summary of Safety and Effectiveness Data. PMA P090026. Quantitative test for determination of [\u20132]proPSA levels","author":"Food and Drug Administration","year":"2012"},{"key":"key20151028091053177_ref1-bib59","doi-asserted-by":"crossref","first-page":"295","DOI":"10.5301\/JBM.2008.220","article-title":"Standardization of PSA measures: a reappraisal and an experience with WHO calibration of Beckman Coulter Access Hybritech total and free PSA","volume":"22","author":"Vignati","year":"2007","journal-title":"Int J Biol Markers"},{"key":"key20151028091053177_ref1-bib60","volume-title":"PMA Approval. Access Hybritech p2PSA on Access Immunoassay Systems","author":"Food and Drug Administration","year":"2012"},{"key":"key20151028091053177_ref1-bib61","volume-title":"Systematic reviews: CRD\u2019s Guidance on Undertaking Reviews in Health Care","author":"Centre for Reviews and Dissemination","year":"2009"},{"key":"key20151028091053177_ref1-bib62","volume-title":"Diagnostics Assessment Programme Manual","author":"National Institute for Health and Care Excellence","year":"2011"},{"key":"key20151028091053177_ref1-bib63","volume-title":"Cochrane Handbook for Systematic Reviews of Diagnostic test Accuracy (Version 10)","author":"Macaskill","year":"2010"},{"key":"key20151028091053177_ref1-bib64","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.1007\/s11606-011-1898-z","article-title":"Chapter 11: challenges in and principles for conducting systematic reviews of genetic tests used as predictive indicators","volume":"27","author":"Jonas","year":"2012","journal-title":"J Gen Intern Med"},{"key":"key20151028091053177_ref1-bib65","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/GIM.0b013e318184137c","article-title":"The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group","volume":"11","author":"Teutsch","year":"2009","journal-title":"Genet Med"},{"key":"key20151028091053177_ref1-bib66","volume-title":"PCA3 Testing for the Diagnosis and Management of Prostate Cancer","author":"Bradley","year":"2013"},{"key":"key20151028091053177_ref1-bib67","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.juro.2013.02.005","article-title":"Comparative effectiveness review: prostate cancer antigen 3 testing for the diagnosis and management of prostate cancer","volume":"190","author":"Bradley","year":"2013","journal-title":"J Urol"},{"key":"key20151028091053177_ref1-bib68","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.trsl.2014.06.006","article-title":"Prostate health index vs. percent free prostate-specific antigen for prostate cancer detection in men with \u2018gray\u2019 prostate-specific antigen levels at first biopsy: systematic review and meta-analysis","volume":"14","author":"Bruzzese","year":"2014","journal-title":"Transl Res"},{"key":"key20151028091053177_ref1-bib69","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1515\/cclm-2012-0410","article-title":"Evaluation of [\u20132] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis","volume":"51","author":"Filella","year":"2013","journal-title":"Clin Chem Lab Med"},{"key":"key20151028091053177_ref1-bib70","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.acra.2014.01.004","article-title":"The value of magnetic resonance imaging in the detection of prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels: a meta-analysis","volume":"21","author":"Zhang","year":"2014","journal-title":"Acad Radiol"},{"key":"key20151028091053177_ref1-bib71","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1373\/clinchem.2005.063289","article-title":"APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer","volume":"52","author":"Groskopf","year":"2006","journal-title":"Clin Chem"},{"key":"key20151028091053177_ref1-bib72","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.urology.2008.08.459","article-title":"PCA3 urine mRNA testing for prostate carcinoma: patterns of use by community urologists and assay performance in reference laboratory setting","volume":"73","author":"Shappell","year":"2009","journal-title":"Urology"},{"key":"key20151028091053177_ref1-bib73","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.clinbiochem.2010.04.062","article-title":"Pre-analytical in-vitro stability of \u20132 proPSA in blood and serum","volume":"43","author":"Semjonow","year":"2010","journal-title":"Clin Biochem"},{"key":"key20151028091053177_ref1-bib74","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.cca.2012.04.015","article-title":"Multi-center analytical performance evaluation of the Access Hybritech p2PSA immunoassay","volume":"413","author":"Sokoll","year":"2012","journal-title":"Clin Chim Acta"},{"key":"key20151028091053177_ref1-bib75","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/pros.20872","article-title":"A \u20132 proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases","volume":"69","author":"Stephan","year":"2009","journal-title":"INC"},{"key":"key20151028091053177_ref1-bib76","volume-title":"NCT01441687. Comparing the Reliability of Expressed Prostatic Secretion (EPS) and Post Massage Urine (PMU) for the Prediction of Prostate Cancer Biopsy Outcome","author":"Clinicaltrials.gov"},{"key":"key20151028091053177_ref1-bib77","volume-title":"Pilot Study: Performance of the Progensa PCA3 Test in Post-oxytocin Urine Specimens","author":"World Health Organization"},{"key":"key20151028091053177_ref1-bib78","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1593\/neo.122144","article-title":"Genome-wide association study identifies genetic determinants of urine PCA3 levels in men","volume":"15","author":"Chen","year":"2013","journal-title":"Neoplasia"},{"key":"key20151028091053177_ref1-bib79","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/sj.bjc.6605485","article-title":"Mutation analysis of the MSMB gene in familial prostate cancer","volume":"102","author":"Kote-Jarai","year":"2010","journal-title":"BJC"},{"key":"key20151028091053177_ref1-bib80","doi-asserted-by":"publisher","first-page":"7933","DOI":"10.1073\/pnas.0902104106","article-title":"Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility","volume":"106","author":"Lou","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20151028091053177_ref1-bib81","doi-asserted-by":"publisher","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"key":"key20151028091053177_ref1-bib82","volume-title":"Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy, Version 100","author":"Reitsma"},{"key":"key20151028091053177_ref1-bib83","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-6-9","article-title":"Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies","volume":"6","author":"Whiting","year":"2006","journal-title":"BMC Med Res Methodol"},{"key":"key20151028091053177_ref1-bib84","volume-title":"NCT01632930. Medical Economics of Urinary PCA3 Test for Prostate Cancer Diagnosis","author":"ClinicalTrials.gov"},{"key":"key20151028091053177_ref1-bib85","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/j.juro.2008.06.038","article-title":"Predicting prostate cancer risk through incorporation of prostate cancer gene 3. [Erratum published in J Urol 2009;181:1507.]","volume":"180","author":"Ankerst","year":"2008","journal-title":"J Urol"},{"key":"key20151028091053177_ref1-bib86","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1016\/j.juro.2010.06.098","article-title":"PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial","volume":"184","author":"Aubin","year":"2010","journal-title":"J Urol"},{"key":"key20151028091053177_ref1-bib87","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1111\/j.1464-410X.2011.10584.x","article-title":"A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy","volume":"109","author":"Auprich","year":"2012","journal-title":"BJU Int"},{"key":"key20151028091053177_ref1-bib88","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.eururo.2010.06.038","article-title":"External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome","volume":"58","author":"Auprich","year":"2010","journal-title":"Eur Urol"},{"key":"key20151028091053177_ref1-bib89","first-page":"96","article-title":"Prostate Cancer Gene 3 urine assay cutoff in diagnosis of prostate cancer a validation study on an italian patient population undergoing first and repeat biopsy","volume":"34","author":"Bollito","year":"2012","journal-title":"Anal Quant Cytol Histol"},{"key":"key20151028091053177_ref1-bib90","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1016\/j.urology.2013.06.078","article-title":"Prostate Cancer Gene 3 and multiparametric magnetic resonance can reduce unnecessary biopsies: decision curve analysis to evaluate predictive models","volume":"82","author":"Busetto","year":"2013","journal-title":"Urology"},{"key":"key20151028091053177_ref1-bib91","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/pros.22538","article-title":"Use of PCA3 in detecting prostate cancer in initial and repeat prostate biopsy patients","volume":"73","author":"Goode","year":"2013","journal-title":"INC"},{"key":"key20151028091053177_ref1-bib92","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.juro.2012.06.017","article-title":"Serum Index Test percent \u20132 proPSA and Prostate Health Index are more accurate than prostate specific antigen and percent fPSA in predicting a positive repeat prostate biopsy","volume":"188","author":"Lazzeri","year":"2012","journal-title":"J Urol"},{"key":"key20151028091053177_ref1-bib93","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.urology.2006.12.014","article-title":"PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy","volume":"69","author":"Marks","year":"2007","journal-title":"Urology"},{"key":"key20151028091053177_ref1-bib94","first-page":"1399","article-title":"PCA3 urinary test versus 1H-MRSI and DCEMR in the detection of prostate cancer foci in patients with biochemical alterations","volume":"31","author":"Panebianco","year":"2011","journal-title":"Anticancer Res"},{"key":"key20151028091053177_ref1-bib95","first-page":"4445","article-title":"PCA3 score vs. PSA free\/total accuracy in prostate cancer diagnosis at repeat saturation biopsy","volume":"31","author":"Pepe","year":"2011","journal-title":"Anticancer Res"},{"key":"key20151028091053177_ref1-bib96","first-page":"6620","article-title":"Prostate cancer detection rate at repeat saturation biopsy: PCPT risk calculator versus PCA3 score versus case-finding protocol","volume":"20","author":"Pepe","year":"2013","journal-title":"Can J Urol"},{"key":"key20151028091053177_ref1-bib97","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.eururo.2010.09.036","article-title":"Prostate cancer detection in the \u2018grey area\u2019 of prostate-specific antigen below 10 ng\/ml: head-to-head comparison of the updated PCPT calculator and Chun\u2019s nomogram, two risk estimators incorporating prostate cancer antigen 3","volume":"59","author":"Perdon\u00e0","year":"2011","journal-title":"Eur Urol"},{"key":"key20151028091053177_ref1-bib98","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1111\/j.1464-410X.2010.09286.x","article-title":"The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies?","volume":"106","author":"Ploussard","year":"2010","journal-title":"BJU Int"},{"key":"key20151028091053177_ref1-bib99","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.juro.2014.01.030","article-title":"The roles of multiparametric magnetic resonance imaging, PCA3 and Prostate Health Index \u2013 which is the best predictor of prostate cancer after a negative biopsy?","author":"Porpiglia","journal-title":"J Urol"},{"key":"key20151028091053177_ref1-bib100","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1016\/j.urolonc.2012.05.002","article-title":"PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and\/or suspicious digital rectal examination. First Latin American experience","volume":"31","author":"Ramos","journal-title":"Urologic Oncol-Semin ORI"},{"key":"key20151028091053177_ref1-bib101","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1111\/j.1464-410X.2010.09330.x","article-title":"Follow-up of men with an elevated PCA3 score and a negative biopsy: does an elevated PCA3 score indeed predict the presence of prostate cancer?","volume":"106","author":"Remzi","year":"2010","journal-title":"BJU Intern"},{"key":"key20151028091053177_ref1-bib102","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.juro.2013.02.3184","article-title":"Head-to-head comparison of Prostate Health Index and urinary PCA3 for predicting cancer at initial or repeat biopsy","volume":"190","author":"Scattoni","year":"2013","journal-title":"J Urol"},{"key":"key20151028091053177_ref1-bib103","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1111\/j.1464-410X.2012.11146.x","article-title":"Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy","volume":"110","author":"Sciarra","year":"2012","journal-title":"BJU Intern"},{"key":"key20151028091053177_ref1-bib104","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1373\/clinchem.2012.195784","article-title":"Multicenter evaluation of [\u20132]proprostate-specific antigen and the prostate health index for detecting prostate cancer","volume":"59","author":"Stephan","journal-title":"Clin Chem"},{"key":"key20151028091053177_ref1-bib105","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.urology.2012.11.069","article-title":"Clinical judgment versus biomarker prostate cancer gene 3: which is best when determining the need for repeat prostate biopsy?","volume":"81","author":"Tombal","year":"2013","journal-title":"Urology"},{"key":"key20151028091053177_ref1-bib106","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/pcan.2011.52","article-title":"Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer","volume":"15","author":"Wu","year":"2012","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"key20151028091053177_ref1-bib107","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1373\/clinchem.2012.195560","article-title":"Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [\u20132]proprostate-specific antigen-based prostate health index for detection of prostate cancer","volume":"59","author":"Stephan","year":"2013","journal-title":"Clin Chem"},{"key":"key20151028091053177_ref1-bib108","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00345-011-0721-0","article-title":"Biopsy and treatment decisions in the initial management of prostate cancer and the role of PCA3; a systematic analysis of expert opinion","volume":"30","author":"Tombal","year":"2012","journal-title":"World J Urol"},{"key":"key20151028091053177_ref1-bib109","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.eururo.2009.03.029","article-title":"Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram","volume":"56","author":"Chun","year":"2009","journal-title":"Eur Urol"},{"key":"key20151028091053177_ref1-bib110","doi-asserted-by":"publisher","first-page":"487","DOI":"10.4103\/1008-682X.125390","article-title":"The PCA3 test for guiding repeat biopsy of prostate cancer and its cut-off score: a systematic review and meta-analysis","volume":"16","author":"Luo","year":"2014","journal-title":"Asian J Androl"},{"key":"key20151028091053177_ref1-bib111","volume-title":"Clinical and Cost Effectiveness of the PROGENSA PCA3 Assay and the Prostate Health Index in the Diagnosis of Prostate Cancer: A Systematic Review and Economic Evaluation [Protocol]","author":"Liverpool Reviews and Implementation Group","year":"2014"},{"key":"key20151028091053177_ref1-bib112","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1136\/bmj.313.7052.275","article-title":"Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ economic evaluation working party","volume":"313","author":"Drummond","year":"1996","journal-title":"BMJ"},{"key":"key20151028091053177_ref1-bib113","doi-asserted-by":"publisher","first-page":"pe260","DOI":"10.1016\/S1569-9056(12)60257-7","article-title":"The cost-effectiveness of prostate cancer detection using Beckman Coulter Prostate Health Index","volume":"11","author":"Heijnsdijk","year":"2012","journal-title":"Eur Urol Suppl"},{"key":"key20151028091053177_ref1-bib114","doi-asserted-by":"publisher","first-page":"358","DOI":"10.3111\/13696998.2012.757552","article-title":"Impact of adoption of a decision algorithm including PCA3 for repeat biopsy on the costs for prostate cancer diagnosis in France","volume":"16","author":"Malavaud","year":"2013","journal-title":"J Med Econ"},{"key":"key20151028091053177_ref1-bib115","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1016\/j.juro.2012.02.184","article-title":"Cost-analysis of PCA3 versus PSA in the detection of prostate cancer in men with a prior negative biopsy","volume":"187","author":"Nepple","year":"2012","journal-title":"J Urol"},{"key":"key20151028091053177_ref1-bib116","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/j.1464-410X.2011.10751.x","article-title":"Cost-effectiveness of prostate health index for prostate cancer detection","volume":"110","author":"Nichol","year":"2011","journal-title":"BJU Int"},{"key":"key20151028091053177_ref1-bib117","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa1201637","article-title":"Quality-of-life effects of prostate-specific antigen screening","volume":"367","author":"Heijnsdijk","year":"2012","journal-title":"N Engl J Med"},{"key":"key20151028091053177_ref1-bib118","volume-title":"Guide to the Methods of Technology Appraisal 2013","author":"National Institute for Health and Care Excellence","year":"2013"},{"key":"key20151028091053177_ref1-bib119","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa1011967","article-title":"Radical prostatectomy versus watchful waiting in early prostate cancer","volume":"364","author":"Bill-Axelson","year":"2011","journal-title":"N Engl J Med"},{"key":"key20151028091053177_ref1-bib120","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.juro.2009.11.043","article-title":"Increasing hospital admission rates for urological complications after transrectal utlrasound guided prostate biopsy","volume":"183","author":"Nam","year":"2010","journal-title":"J Urol"},{"key":"key20151028091053177_ref1-bib121","doi-asserted-by":"publisher","first-page":"d7894","DOI":"10.1136\/bmj.d7894","article-title":"Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study","volume":"344","author":"Rosario","year":"2012","journal-title":"BMJ"},{"key":"key20151028091053177_ref1-bib122","volume-title":"Unit Costs of Health and Social Care 2013","author":"Curtis","year":"2013"},{"key":"key20151028091053177_ref1-bib123","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/ijc.2910490411","article-title":"The impact of a breast cancer screening programme on quality-adjusted life-years","volume":"49","author":"de Haes","year":"1991","journal-title":"Int J Cancer"},{"key":"key20151028091053177_ref1-bib124","volume-title":"The Use of Health State Utility Values in Decision Models","author":"Ara","year":"2011"},{"key":"key20151028091053177_ref1-bib125","doi-asserted-by":"crossref","first-page":"286","DOI":"10.6004\/jnccn.2013.0040","article-title":"Counterpoint: Prostate-specific antigen velocity is not of value for early detection of cancer","volume":"11","author":"Vickers","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"key20151028091053177_ref1-bib126","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1200\/JCO.2008.18.1685","article-title":"Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer","volume":"27","author":"Vickers","year":"2009","journal-title":"J Clin Oncol"},{"key":"key20151028091053177_ref1-bib127","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.urology.2010.06.019","article-title":"Everything you always wanted to know about evaluating prediction models (but were too afraid to ask)","volume":"76","author":"Vickers","year":"2010","journal-title":"Urology"},{"key":"key20151028091053177_ref1-bib128","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s13277-013-0739-6","article-title":"PCA3 in the detection and management of early prostate cancer","volume":"34","author":"Filella","year":"2013","journal-title":"Tumour Biol"},{"key":"key20151028091053177_ref1-bib129","doi-asserted-by":"publisher","first-page":"5012","DOI":"10.1038\/srep05012","article-title":"Diagnostic ability of %p2PSA and prostate health index for aggressive prostate cancer: a meta-analysis","volume":"4","author":"Wang","year":"2014","journal-title":"Sci Rep"},{"key":"key20151028091053177_ref1-bib130","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/jncimonographs\/lgs041","article-title":"The Prostate Cancer Intervention Versus Observation Trial: VA\/NCI\/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy with watchful waiting for men with clinically localized prostate cancer","volume":"2012","author":"Wilt","year":"2012","journal-title":"J Natl Cancer Inst Monogr"},{"key":"key20151028091053177_ref1-bib131","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/pcan.2011.31","article-title":"Predictive value of digital rectal examination for prostate cancer detection is modified by obesity","volume":"14","author":"Chu","year":"2011","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"key20151028091053177_ref1-bib132","doi-asserted-by":"publisher","first-page":"91","DOI":"10.7326\/0003-4819-126-1-199701010-00026","article-title":"\u2018Sensitivity\u2019 and \u2018specificity\u2019 reconsidered: the meaning of these terms in analytical and diagnostic settings","volume":"126","author":"Saah","year":"1997","journal-title":"Ann Intern Med"},{"key":"key20151028091053177_ref1-bib133","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.fitote.2010.09.011","article-title":"Accuracy, precision, and reliability of chemical measurements in natural products research","volume":"82","author":"Betz","year":"2011","journal-title":"Fitoterapia"},{"key":"key20151028091053177_ref1-bib134","volume-title":"Method Validation","author":"Labnetwork"},{"key":"key20151028091053177_ref1-bib135","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.jclinepi.2009.08.024","article-title":"Appropriate statistical methods are required to assess diagnostic tests for replacement, add-on, and triage","volume":"63","author":"Hayen","year":"2010","journal-title":"J Clin Epidemiol"},{"key":"key20151028091053177_ref1-bib136","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1177\/0272989X06295361","article-title":"Decision curve analysis: a novel method for evaluating prediction models","volume":"26","author":"Vickers","year":"2006","journal-title":"Med Decis Making"},{"key":"key20151028091053177_ref1-bib137","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1177\/0272989X07312725","article-title":"Decision curve analysis: a discussion","volume":"28","author":"Steyerberg","year":"2008","journal-title":"Med Decis Making"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta19870\/hta19870.xml","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2002363","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta19870\/hta19870.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2002773","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T15:28:33Z","timestamp":1692113313000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/hta19870\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":137,"journal-issue":{"issue":"87","published-online":{"date-parts":[[2015,10]]}},"alternative-id":["10.3310\/hta19870"],"URL":"https:\/\/doi.org\/10.3310\/hta19870","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"}]}}